Patient-reported outcomes are superior in patients with type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study
However, a shortage doesn't negate the need for a legal, safe, and approved source drug, which in this case, ironically, are the ones in short supply
Catalent Sector: Drug delivery technologies HQ: Morrisville, NC Year Founded: 2007 Key Leaders: Alessandro Maselli, President and CEO Number of Employees: ~17,000 Stage: Subsidiary of Novo Holdings A/S (private) Financial Snapshot: The market cap was approximately $11.52 billion before the company went private
Rare adverse events that might emerge in large studies could remain invisible in community discussions
How much protein should GLP-1 snacks have